| Description | This product is a human monoclonal antibody that reacts with FGFR1. The antibody is expressed with mammalian cell transient expression system, serum-free and purified by affinity chromatography. The purity and integrity are tested via SDS-PAGE and SEC-HPLC analysis. Given an antigen, additional QC measures are also desired such as affinity testing and binding validation. Specifically, the antibody is provided in multiple formats for in vivo and in vitro assays. The Invivo version features greater than 95% purity, ultra-low endotoxin levels (<1 EU/mg or 0.1 EU/mg), and is preservative, stabilizer, and carrier protein-free. |
| Clonality | Monoclonal |
| Host Species | Human |
| Target Species | Human |
| Isotype | IgG |
| Expression Species | HEK293F or CHO |
| Conjugation | None |
| Purity | >95%, determined by SDS-PAGE and/or SEC-HPLC |
| Endotoxin | <1 EU/mg, determined by LAL method |
| Purification | Protein A affinity purified |
| Sterility | 0.2 μM filtered |
| Formulation | PBS, pH 7.4 |
| Preservation | No preservatives |
| Stabilizer | No stabilizers |
| Storage | Store at 4⁰C within a week. For longer storage, aliquot and store at -20⁰C. |
| Application | WB; ELISA; Neut |
| Application Notes | The antibody is recommended for detection of FGFR1 by ELISA, Neut assays. |
| ELISA | Enzyme-Linked Immunosorbent Assay Protocol |
| WB | Western Blot Protocol |
| FC | Flow Cytometry Protocol |
| Target | FGFR1 |
| Alternative Name | FGFR1; fibroblast growth factor receptor 1; CEK; FLG; HH2; OGD; FLT2; KAL2; BFGFR; CD331; FGFBR; FLT-2; HBGFR; N-SAM; FGFR-1; HRTFDS; bFGF-R-1; FGFR1/PLAG1 fusion; proto-oncogene c-Fgr; FMS-like tyrosine kinase 2; hydroxyaryl-protein kinase; fms-related tyrosine kinase 2; heparin-binding growth factor receptor; basic fibroblast growth factor receptor 1 |
| Gene ID | 2260 |
| UniProt | P11362 |
| Research Area | Cardiovascular |
Figure 1 Anti FGFR1 Monoclonal Antibody (V3S-0622-YC1620) in SDS-PAGE
SDS-PAGE analysis of V3S-0622-YC1620 in non-reduced (lane 1) and reduced (lane 2) conditions. Gel stained for 30 minutes with Coomassie Blue. As a result of different β-mercaptoethanol-reduced proteins (Heavy chain and Light chain) migrate as about 50 kDa and 30 kDa, respectively.
Figure 1 Anti FGFR1 Monoclonal Antibody (V3S-0622-YC1620) in SDS-PAGE
Figure 2 Anti-FGFR1 Monoclonal Antibody (V3S-0622-YC1620) in SEC-HPLC
The purity of V3S-0622-YC1620 was greater than 95% as determined by HPLC.
Figure 2 Anti-FGFR1 Monoclonal Antibody (V3S-0622-YC1620) in SEC-HPLC
Figure 3 Anti-FGFR1 Monoclonal Antibody (V3S-0622-YC1620) in WB
Western blot analysis of V3S-0622-YC1620 with recombinant human FGFR1 Protein (His Tag).
Lane 1: Non-reducing human FGFR1
Lane 2: Reducing human FGFR1
Figure 3 Anti-FGFR1 Monoclonal Antibody (V3S-0622-YC1620) in WB
Figure 4 Anti-FGFR1 Monoclonal Antibody (V3S-0622-YC1620) in ELISA
ELISA analysis of V3S-0622-YC1620 was performed by coating with recombinant human FGFR1 protein (His Tag).
Figure 4 Anti-FGFR1 Monoclonal Antibody (V3S-0622-YC1620) in ELISA
